Artivion
AORT
21.26
+0.05
+0.24%
Artivion
US · AORT
#3212 by market cap
21.26
+0.05
+0.24%
Live - 5344 symbols - heartbeat 107s ago
· 2026-10-09 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- Total institutional ownership rose 0.2 percentage points.
Institutional ownership
- Held by institutions
- 96.54% +0.24pp
- Institutions
- 255
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund73.44%
Hedge Fund10.53%
Public Company6.40%
Individual/Insider5.07%
VC/PE Fund3.92%
Private Company1.14%
Government Pension Fund0.82%
Insurance Company0.27%
Top holders as of 2026-06-30
BlackRock
13.69% · 6.67M sh
Macquarie Investment Management Business Trust
6.53% · 3.18M sh
Morgan Stanley
4.78% · 2.33M sh
Vanguard Capital Management, LLC
4.75% · 2.32M sh
Juniper Investment Company, LLC
4.14% · 2.02M sh
FMR
4.03% · 1.96M sh
State Street Global Advisors
3.81% · 1.86M sh
Ophir Asset Management Pty Ltd
3.69% · 1.80M sh
Perceptive Advisors LLC
3.56% · 1.74M sh
Conestoga Capital Advisors, LLC
3.33% · 1.62M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 20 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| James Mackin | Chairperson & CEO | 1.80% |
| John Davis | Senior Vice President of Global Sales & Marketing | 0.47% |
| Lance Berry | Chief Financial Officer | 0.43% |
| Jean Holloway | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 0.38% |
| Daniel Bevevino | Independent Director | 0.32% |
| Thomas Ackerman | Independent Director | 0.32% |
| Amy Horton | VP & Chief Accounting Officer | 0.29% |
| Jon Salveson | Independent Director | 0.28% |
| James Bullock | Independent Director | 0.16% |
| Jeffrey Burbank | Independent Director | 0.13% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-09 | Andrew Green | Senior Vice President of Regulatory & Quality | Open Market Disposition | -11,480 | $24.97 |
| 2026-09-02 | Andrew Green | Senior Vice President of Regulatory & Quality | Open Market Disposition | -8,003 | $26.02–27.27 |
| 2026-09-02 | Andrew Green | Senior Vice President of Regulatory & Quality | Intent to Sell (Form 144) | -1,493 | $26.02 |
| 2026-09-01 | Andrew Green | Senior Vice President of Regulatory & Quality | Intent to Sell (Form 144) | -6,510 | $27.27 |
| 2026-08-26 | Marshall Stanton | Senior VP of Clinical Research & Chief Medical Officer | Intent to Sell (Form 144) | -7,400 | $26.85 |
| 2026-08-18 | James Mackin | Chairperson & CEO | Open Market Disposition | -70,000 | $28.96 |
| 2026-08-13 | Andrew Green | Senior Vice President of Regulatory & Quality | Open Market Disposition | -616 | $28.55 |
| 2026-08-13 | Lance Berry | Chief Financial Officer | Open Market Disposition | -715 | $28.55 |
| 2026-08-11 | Jean Holloway | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | Open Market Disposition | -977 | $28.49 |
| 2026-06-10 | Andrew Green | Senior Vice President of Regulatory & Quality | Derivative Exercise and Sale | -44,001 | $11.03–20.71 |
| 2026-06-01 | Anthony Semedo | Independent Director | Other Acquisition | +6,325 | -- |
| 2026-06-01 | Anthony Semedo | Independent Director | Other Disposition | -6,325 | -- |
| 2026-05-31 | Andrew Green | Senior Vice President of Regulatory & Quality | Initial Statement of Beneficial | 0 | -- |
| 2026-05-17 | James Bullock | Independent Director | Other Acquisition | +7,576 | -- |
| 2026-05-17 | Thomas Ackerman | Independent Director | Other Acquisition | +7,576 | -- |
| 2026-05-17 | Anthony Semedo | Independent Director | Other Acquisition | +7,576 | -- |
| 2026-05-17 | Daniel Bevevino | Independent Director | Other Acquisition | +7,576 | -- |
| 2026-05-17 | Jeffrey Burbank | Independent Director | Other Acquisition | +7,576 | -- |
| 2026-05-17 | Jon Salveson | Independent Director | Other Acquisition | +7,576 | -- |
| 2026-05-17 | Marna Borgstrom | Independent Director | Other Acquisition | +7,576 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-09 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Artivion discussion 0 comments